Figure 4.

MITO-66-conditioned CAR T cells protect against cancer recurrence

(A) Experimental scheme depicting CD19-CAR T cell treatment of NALM6 leukemia-bearing mice following in vivo rechallenge for three times with 2 × 10⁶ and finally 5 × 10⁶ NALM6 cells. CAR T cells were prepared from four different donors and performed in two independent experiments. CAR T cells from each donor were transferred in five to seven different NALM6-bearing mice. Throughout the experiment, some mice were lost because of graft-versus-host disease. (B–E) NALM6 tumor burden measured by bioluminescence at the indicated days post-initial NALM6 engraftment. (F–I) Number of transferred CD3 T cells in the blood of mice analyzed by flow cytometry at the indicated time points. (J and K) Percentage of CD62L-positive cells in the CD4 (E) or CD8 (F) T cell population in the blood at day 10 post-ACT. Data are represented as mean ± SD. Statistics are based on unpaired two-tailed Student’s t test (D) or two-way ANOVA (F–K).